ZA983720B - Aldose reductase inhibition in preventing or reversing diabetic cardiomyopathy. - Google Patents

Aldose reductase inhibition in preventing or reversing diabetic cardiomyopathy.

Info

Publication number
ZA983720B
ZA983720B ZA9803720A ZA983720A ZA983720B ZA 983720 B ZA983720 B ZA 983720B ZA 9803720 A ZA9803720 A ZA 9803720A ZA 983720 A ZA983720 A ZA 983720A ZA 983720 B ZA983720 B ZA 983720B
Authority
ZA
South Africa
Prior art keywords
preventing
aldose reductase
diabetic cardiomyopathy
reductase inhibition
reversing diabetic
Prior art date
Application number
ZA9803720A
Other languages
English (en)
Inventor
Brian Frank Johnson
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of ZA983720B publication Critical patent/ZA983720B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA9803720A 1997-05-05 1998-05-04 Aldose reductase inhibition in preventing or reversing diabetic cardiomyopathy. ZA983720B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4582297P 1997-05-05 1997-05-05

Publications (1)

Publication Number Publication Date
ZA983720B true ZA983720B (en) 1999-11-04

Family

ID=21940071

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9803720A ZA983720B (en) 1997-05-05 1998-05-04 Aldose reductase inhibition in preventing or reversing diabetic cardiomyopathy.

Country Status (17)

Country Link
US (1) US5990111A (de)
EP (1) EP0880964B1 (de)
JP (1) JP3010153B2 (de)
KR (1) KR19980086748A (de)
AT (1) ATE277607T1 (de)
AU (1) AU725621B2 (de)
CA (1) CA2236553C (de)
DE (1) DE69826561T2 (de)
DK (1) DK0880964T3 (de)
ES (1) ES2227773T3 (de)
HU (1) HUP9801022A3 (de)
IL (1) IL124236A (de)
MY (1) MY136261A (de)
NZ (1) NZ330359A (de)
PT (1) PT880964E (de)
TW (1) TW589184B (de)
ZA (1) ZA983720B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413965B1 (en) * 1999-06-30 2002-07-02 Pfizer Inc. Compositions and treatment for diabetic complications
US6555540B1 (en) * 1999-06-30 2003-04-29 Pfizer Inc Combinations of aldose reductase inhibitors and selective cyclooxygenase-2 inhibitors
US6426341B1 (en) * 1999-06-30 2002-07-30 Pfizer Inc. Treatment for diabetic complications
AU7063300A (en) * 1999-08-23 2001-03-19 University Of Virginia Patent Foundation Method and apparatus for predicting the risk of hypoglycemia
US20020068740A1 (en) * 1999-12-07 2002-06-06 Mylari Banavara L. Combination of aldose reductase inhibitors and antihypertensive agents for the treatment of diabetic complications
US6380200B1 (en) * 1999-12-07 2002-04-30 Pfizer, Inc. Combination of aldose reductase inhibitors and selective serotonin reuptake inhibitors for the treatment of diabetic complications
CO5271699A1 (es) 2000-01-24 2003-04-30 Pfizer Prod Inc Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
CN1526023B (zh) * 2001-03-30 2012-09-05 香港中文大学 针对醛糖还原酶基因的引物和探针在制备用于确定白内障风险的组合物中的应用
WO2003105864A1 (en) * 2002-06-13 2003-12-24 Board Of Regents, The University Of Texas System Methods and compositions involving aldose reductase inhibitors
US20110092566A1 (en) * 2004-11-19 2011-04-21 Srivastava Satish K Treatment of cancer with aldose reductase inhibitors
CA2685202C (en) 2007-03-23 2017-11-28 The Board Of Regents Of The University Of Texas System Methods for treating allergic asthma
US20090270490A1 (en) * 2008-04-24 2009-10-29 The Board Of Regents Of The University Of Texas System Methods involving aldose reductase inhibition
AU2011348074B2 (en) 2010-12-23 2016-04-28 The Board Of Regents Of The University Of Texas System Methods for treating COPD

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL80475A (en) * 1985-11-07 1993-01-31 Pfizer Heterocyclic-substituted 4-oxo (or thio)-3h- phthalazinyl-acetic acid derivatives and pharmaceutical compositions containing them
US4748280A (en) * 1985-11-07 1988-05-31 Pfizer Inc. Certain chlorination process for preparing 2-chloro-1,1,1-(C1 -C6)
US4939140A (en) * 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
US4743611A (en) * 1986-07-02 1988-05-10 American Home Products Corp. Naphthalenylsulfonylimidazolidinediones and their thioxo analogs useful as aldose reductase inhibitors
JPH0676391B2 (ja) * 1987-06-09 1994-09-28 フアイザー・インコーポレイテツド ベンゾチアゾール等の複素環側鎖を有するオキソフタラジニル酢酸類の製造方法
US4868301A (en) * 1987-06-09 1989-09-19 Pfizer Inc. Processes and intermediates for the preparation of oxophthalazinyl acetic acids having benzothiazole or other heterocyclic side chains
EP0322153A3 (de) * 1987-12-21 1990-08-16 Pfizer Inc. Heterozyklyl Oxophtalazynyl-Essigsäuren
US4954629A (en) * 1989-05-11 1990-09-04 Pfizer Inc. Process and intermediates for the preparation of oxophthalazinyl acetic acids and analogs thereof
US5164391A (en) * 1989-09-20 1992-11-17 Sanwa Kagaku Kenkyusho Co., Ltd. Hydantoin derivatives for treating complications of diabetes and circulatory diseases
FI922308L (fi) * 1989-12-15 1992-05-21 Pfizer Substituerade oxoftalazinylaettiks- syror och deras analoger.
US5064830A (en) * 1990-08-02 1991-11-12 Pfizer Inc. Lowering of blood uric acid levels
WO1994007867A1 (en) * 1992-09-28 1994-04-14 Pfizer Inc. Substituted pyrimidines for control of diabetic complications
US5391551A (en) * 1993-05-10 1995-02-21 Pfizer Inc. Method of lowering blood lipid levels
US5834466A (en) * 1994-12-22 1998-11-10 The Regents Of The University Of California Method for protecting of heart by limiting metabolic and ionic abnormalities developed during ischemia, following ischemia or resulting from ischemia

Also Published As

Publication number Publication date
DK0880964T3 (da) 2004-12-27
NZ330359A (en) 2000-06-23
EP0880964A3 (de) 2002-07-17
HUP9801022A3 (en) 2001-10-29
KR19980086748A (ko) 1998-12-05
PT880964E (pt) 2004-12-31
EP0880964B1 (de) 2004-09-29
AU725621B2 (en) 2000-10-19
ES2227773T3 (es) 2005-04-01
DE69826561D1 (de) 2004-11-04
JP3010153B2 (ja) 2000-02-14
EP0880964A2 (de) 1998-12-02
US5990111A (en) 1999-11-23
TW589184B (en) 2004-06-01
CA2236553C (en) 2002-10-29
IL124236A (en) 2003-01-12
MY136261A (en) 2008-09-30
DE69826561T2 (de) 2006-03-09
ATE277607T1 (de) 2004-10-15
HUP9801022A2 (hu) 2000-03-28
AU6380198A (en) 1998-11-05
JPH10316588A (ja) 1998-12-02
CA2236553A1 (en) 1998-11-05

Similar Documents

Publication Publication Date Title
IL158593A0 (en) Novel, arylsulfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders
BR0009951B1 (pt) composiÇço de higiene pessoal.
WO2003053383A3 (fr) Utilisation cosmetique d’au moins une hydrophobine pour le traitement des matieres keratiniques
ZA200202449B (en) Use of retigabin for treating neuropathic pain.
ZA939161B (en) Wastewater treatment.
AU6380198A (en) Aldose reductase inhibition in preventing or reversing diabetic cardiomyopathy
ZA9811507B (en) Combination effective for the treatment of impotence.
YU89503A (sh) Korišćenje osteopontina za lečenje i/ili prevenciju neuroloških bolesti
BR0309095A (pt) Uso de osteoprotegerina para o tratamento e/ou prevenção de doença fibrótica
EP0909561A3 (de) Verwendung der Reboxetin zur Behandlung der Aufmerksamkeitsmangel/Hyperaktivität Störung
EP0930067A3 (de) Mmp inhibitoren zur behandlung von okularer angiogenesis
SG166661A1 (en) Precursor compounds
ZA200105690B (en) Novel treatment.
AU2001275450A1 (en) Bismuth compounds for the treatment and prevention of mucositis
AU2636602A (en) Use of sarp-1 for the treatment and/or prevention of scleroderma
ZA200004363B (en) Treatment or prevention of coccidiosis.
EP1251847A4 (de) Neue verwendung von prodigiosin zur behandlung von diabetes mellitus
WO2002038122A3 (fr) Compositions exemptes de protease, comprenant une glycosidase
ZA200103250B (en) The treatment of immunomodulatory related and other diseases or conditions.
AU1278700A (en) Novel therapeutic use of 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergoline
ZA994585B (en) Treatment of water.
AU2003297522A8 (en) Bacteriophage-encoded antibacterial enzyme for the treatment and prevention of gingivitis and root surface caries
KR950009067U (ko) 소음방지용 배수구
ZA996546B (en) Treatment of water.
ZA994586B (en) Treatment of water.